20:53 , Mar 20, 2019 |  BC Innovations  |  Translation in Brief

Sangamo’s ZFN linkers finger new options

Sangamo is using new linkers to expand the structural variety of the ZFNs it designs and increase the odds of finding ZFNs with high editing efficiency and specificity for their targets. Conventional zinc finger nucleases...
02:41 , Mar 15, 2019 |  BC Innovations  |  Product Development

Fresh AIMMs for elite responders

AIMM Therapeutics B.V.’s elite responder platform has identified mAbs that distinguish tumor and healthy cells based on protein modifications. The company is one of a handful of players mining the immune systems of cancer patients...
17:37 , Mar 8, 2019 |  BC Week In Review  |  Company News

CARsgen's BCMA CAR T moving to clinic in China

CARsgen said CT053 (CAR-BCMA) received IND clearance from China's National Medical Products Administration (NMPA). CARsgen Therapeutics Co. Ltd. (Shanghai, China) said it is also planning to submit this year an IND to FDA for the...
17:33 , Mar 8, 2019 |  BC Week In Review  |  Financial News

Genome editing company Precision proposes $100M IPO

With plans to bring an allogeneic CAR T immunotherapy into the clinic, Precision BioSciences Inc. (Durham, N.C.) proposed March 1 to raise up to $100 million in an IPO on NASDAQ. Precision plans to start...
22:34 , Mar 7, 2019 |  BC Extra  |  Preclinical News

Beyond cancer: CAR T cells treat lupus in mice

University of Tennessee researchers have shown that CD19-targeted CAR T cells could help treat lupus, suggesting the approach could be applied to diseases beyond cancer. Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by...
20:41 , Mar 7, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: February 2019

New Therapeutic Targets and Biomarkers: February 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during February. Therapeutic targets are defined as any protein, gene or other molecule...
22:36 , Mar 5, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting NR4A1, NR4A2 and N4RA3 in CAR Ts to enhance efficacy in solid tumors

DISEASE CATEGORY: Cancer INDICATION: Melanoma; colorectal cancer Mouse studies suggest inhibiting NR4A1, NR4A2 and NR4A3 in CAR T cells could enhance the cells' efficacy in melanoma, colorectal cancer and other solid tumor types. In CD8+...
21:16 , Mar 5, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting GM-CSF in CAR Ts to prevent therapy-induced cytokine release syndrome

DISEASE CATEGORY: Inflammation INDICATION: Cytokine release syndrome (CRS) Cell culture studies suggest inhibiting GM-CSF produced by CAR T cells could help prevent CRS in lymphoma patients receiving CAR T therapies. In a co-culture assay in...
00:53 , Mar 2, 2019 |  BC Extra  |  Financial News

Genome editing company Precision proposes $100M IPO

With plans to bring an allogeneic CAR T immunotherapy into the clinic, Precision BioSciences Inc. (Durham, N.C.) proposed Friday to raise up to $100 million in an IPO on NASDAQ. Precision plans to start this...
13:02 , Feb 28, 2019 |  BC Extra  |  Preclinical News

Removing genes from CAR Ts to improve efficacy, safety

Two studies have identified genes that could be knocked out from CAR T cells to improve efficacy or safety. While CAR T cells are effective against B cell malignancies, their efficacy in solid tumors has...